People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| EXCELLOS, Inc | — | Biotechnology | Series B | $20.0M | $52.9M | 2023 |
Deval Lashkari, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Deval Lashkari, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| DEVAL LASHKARI | 1 | 6 |
| PAUL GROSSMAN | 1 | 3 |
| David Wellis, Ph.D. | 1 | 2 |
| Alex Herzik | 1 | 1 |
| Terance Kinninger | 1 | 1 |
| Robert Finzi | 1 | 1 |
| Paul Grossman, Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.